Literature DB >> 25182453

The shrinking or disappearing observed treatment effect.

Christy Chuang-Stein1, Simon Kirby.   

Abstract

It is frequently noted that an initial clinical trial finding was not reproduced in a later trial. This is often met with some surprise. Yet, there is a relatively straightforward reason partially responsible for this observation. In this article, we examine this reason by first reviewing some findings in a recent publication in the Journal of the American Medical Association. To help explain the non-negligible chance of failing to reproduce a previous positive finding, we compare a series of trials to successive diagnostic tests used for identifying a condition. To help explain the suspicion that the treatment effect, when observed in a subsequent trial, seems to have decreased in magnitude, we draw a conceptual analogy between phases II-III development stages and interim analyses of a trial with a group sequential design. Both analogies remind us that what we observed in an early trial could be a false positive or a random high. We discuss statistical sources for these occurrences and discuss why it is important for statisticians to take these into consideration when designing and interpreting trial results.
Copyright © 2014 John Wiley & Sons, Ltd.

Keywords:  overestimation; regression to the mean; shrinkage

Mesh:

Year:  2014        PMID: 25182453     DOI: 10.1002/pst.1633

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  6 in total

1.  Selection bias, investment decisions and treatment effect distributions.

Authors:  Stig Johan Wiklund; Carl-Fredrik Burman
Journal:  Pharm Stat       Date:  2021-05-17       Impact factor: 1.234

2.  A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.

Authors:  Terence Fullerton; Brendon Binneman; William David; Marielle Delnomdedieu; James Kupiec; Peter Lockwood; Jessica Mancuso; Jeffrey Miceli; Joanne Bell
Journal:  Alzheimers Res Ther       Date:  2018-04-05       Impact factor: 6.982

3.  Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.

Authors:  Stella Erdmann; Marietta Kirchner; Heiko Götte; Meinhard Kieser
Journal:  BMC Med Res Methodol       Date:  2020-10-09       Impact factor: 4.615

4.  The need for thorough phase II studies in medicines development for Alzheimer's disease.

Authors:  Julian A Gray; David Fleet; Bengt Winblad
Journal:  Alzheimers Res Ther       Date:  2015-10-26       Impact factor: 6.982

5.  The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.

Authors:  T Burt; K S Button; Hhz Thom; R J Noveck; M R Munafò
Journal:  Clin Transl Sci       Date:  2017-07-04       Impact factor: 4.689

6.  John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.

Authors:  Shannon M Smith; Maurizio Fava; Mark P Jensen; Omar B Mbowe; Michael P McDermott; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2020-09       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.